Editorial
Rev Diabet Stud,
2009,
6(4):230-236 |
DOI 10.1900/RDS.2009.6.230 |
Alpha-Lipoic Acid and Diabetic Neuropathy
Natalia Vallianou, Angelos Evangelopoulos, Pavlos Koutalas
Department of Internal Medicine, Polykliniki General Hospital, 3 Pireos Str., 10552 Athens, Greece
Address correspondence to: Natalia Vallianou, e-mail: natalia.vallianou@hotmail.com
Manuscript submitted November 13, 2009; resubmitted December 29, 2009; accepted December 30, 2009.
Keywords: diabetes, alpha-lipoic acid, reactive oxygen species, advanced glycation end products, nuclear factor-kappaB, protein kinase C
Abstract
Diabetic neuropathy presents a major public health problem. It is defined by the symptoms and signs of peripheral nerve dysfunction in diabetic patients, in whom other causes of neuropathy have been excluded. Pathogenetic mechanisms that have been implicated in diabetic neuropathy are: a) increased flux through the polyol pathway, leading to accumulation of sorbitol, a reduction in myo-inositol, and an associated reduced Na+-K+-ATPase activity, and b) endoneurial microvascular damage and hypoxia due to nitric oxide inactivation by increased oxygen free radical activity. Alpha-lipoic acid seems to delay or reverse peripheral diabetic neuropathy through its multiple antioxidant properties. Treatment with alpha-lipoic acid increases reduced glutathione, an important endogenous antioxidant. In clinical trials, 600 mg alpha-lipoic acid has been shown to improve neuropathic deficits. This review focuses on the relationship of alpha-lipoic acid and auto-oxidative glycosylation. It discusses the impact of alpha-lipoic acid on hyperglycemia-induced oxidative stress, and examines the role of alpha-lipoic acid in preventing glycation process and nerve hypoxia.
Fulltext:
HTML
, PDF
(126KB)
This article has been cited by other articles:
|
Diabetic neuropathy: cellular mechanisms as therapeutic targets
Vincent AM, Callaghan BC, Smith AL, Feldman EL
Nat Rev Neurol 2011. 7(10):573-583
|
|
|
Diabetes and alpha lipoic acid
Golbidi S, Badran M, Laher I
Front Pharmacol 2011. 2:69
|
|
|
Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy
McIlduff CE, Rutkove SB
Ther Clin Risk Manag 2011. 7:377-85
|
|
|
Advanced glycation endproducts and their pathogenic roles in neurological disorders
Münch G, Westcott B, Menini T, Gugliucci A
Amino Acids 2010. Oct 14, epub ahead of print
|
|
|
Diabetic neuropathic pain: an update and novel pharmacological strategies for relief of pain
Taliyan R, Sharma PL
J Med Sci 2010. 10(4):93-109
|
|
|
The role of oxidative stress and anti-oxidant treatment in platinum-induced peripheral neurotoxicity
Carozzi VA, Marmiroli P, Cavaletti G
Curr Cancer Drug Targets 2010. 10(7):670-682
|
|
|